On September 7, 2001, Adams, Jerry L.; Boehm, Jeffrey C.; Hall, Ralph F.; Taggart, John J. published a patent.Computed Properties of 357935-97-8 The title of the patent was Preparation of 1,5-disubstituted-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-ones for treatment of CSBP/p38 kinase mediated diseases. And the patent contained the following:
The title compounds (I) [wherein R1 = (un)substituted (hetero)aryl; R2 = H or (un)substituted (cyclo)alkyl(alkyl), (hetero)aryl(alkyl), or heterocyclyl(alkyl); R3 = (un)substituted (cyclo)alkyl(alkyl), (hetero)aryl(alkyl), or heterocyclyl(alkyl); Y = a bond, CRb, CO, NRd, O, or SOm; Rb = H, alkyl, NRc, OH, SH, alkoxy, or SOm-alkyl; Rc and Rd = independently H or alkyl; X = R2, OR2, SOmR2, or (un)substituted (CH2)nNH2; m = 0-2; n = 0-10; or pharmaceutically acceptable salts thereof] were prepared as CSBP/p38 kinase inhibitors. For example, 4,6-dichloro-2-methylsulfanylpyrimidine-5-carbonitrile was condensed with aniline, followed by arylation with PhB(OH)2, reduction of the nitrile using LAH in Et2O, and cyclocondensation of the diamine with COCl2 in toluene and pyridine, to give II. Representative compounds I inhibited CSBP/p38 kinase with IC50 values of < 100 μM. Applications of I to a wide variety of arthritic, inflammatory, proliferative, and viral conditions are specifically claimed. The experimental process involved the reaction of 1-Ethylpiperidin-4-amine dihydrochloride(cas: 357935-97-8).Computed Properties of 357935-97-8
The Article related to pyrimidopyrimidinone preparation csbp p38 kinase inhibitor, antiarthritic antiinflammatory immunosuppressant antiviral antitumor pyrimidopyrimidinone preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Computed Properties of 357935-97-8
Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem